The overwhelming majority of semaglutide adverse reactions are gastrointestinal, scale with the dose, and affect a substantial minority of trial participants. In randomised trials of adults treated for weight management, nausea was reported by 44% of patients receiving Wegovy injection 2.4 mg weekly compared with 16% on placebo. In diabetes trials, nausea affected 15.8% of patients taking Ozempic 0.5 mg and 20.3% taking 1 mg compared with 6.1% on placebo. Most of what people report is digestive, and it scales with the dose. Acute pancreatitis, gallbladder disease and acute kidney injury are different: each carries its own label warning, and the Wegovy trial rates are given below.
The Verdict
The Shape of Semaglutide Adverse Reactions
Clinical trial data establish that semaglutide adverse reactions are primarily digestive, dose-dependent, and concentrated during dose titration. In the pooled STEP 1 to 3 analysis of 2,117 participants taking once-weekly subcutaneous semaglutide 2.4 mg, published by Wharton and colleagues in Diabetes, Obesity and Metabolism, 99.5% of gastrointestinal adverse events were non-serious and 98.1% were mild or moderate. Severe events occurred in 4.1% of participants receiving semaglutide 2.4 mg versus 0.9% on placebo.
Nausea represents the single most common symptom across clinical trials, though reported rates depend on the product, formulation, and target dose. Under the FDA-approved Wegovy prescribing information, nausea occurred in 44% of adult weight-management participants on 2.4 mg injection versus 16% on placebo. Under the Ozempic prescribing information for type 2 diabetes, nausea was reported by 15.8% of patients taking 0.5 mg and 20.3% taking 1 mg weekly compared with 6.1% on placebo. The oral formulation, evaluated in the Rybelsus prescribing information, documented nausea in 11% of patients on 7 mg daily and 20% on 14 mg daily versus 6% on placebo.
Gastrointestinal symptoms do not drive the weight reduction observed in clinical trials. In the Wharton pooled analysis, participants who experienced gastrointestinal adverse events achieved weight losses of 17.3%, 11.4%, and 17.7% across STEP 1, 2, and 3, whereas participants without gastrointestinal events achieved 15.7%, 9.6%, and 17.1% reductions. Formal mediation analysis confirmed that less than 1 percentage point of the additional weight loss seen with semaglutide over placebo was mediated by gastrointestinal adverse events.
Common Gastrointestinal Adverse Reactions and Label Frequencies
In the Wegovy adult weight-reduction trials, 73% of adults on Wegovy injection 2.4 mg weekly reported a gastrointestinal adverse reaction, against 47% on placebo, and almost all of those events were mild or moderate. Diarrhoea affected 30% of patients on Wegovy compared with 16% on placebo. Constipation was documented in 24% of patients on drug versus 11% on placebo, and vomiting occurred in 24% on Wegovy versus 6% on placebo.
The placebo rates provide an essential benchmark for evaluating symptoms attributed to the drug. In the same weight-reduction trials, 10% of participants receiving placebo reported abdominal pain, 10% reported headache, and 5% reported fatigue. In the Ozempic trials, gastrointestinal reactions overall occurred in 15.3% on placebo, 32.7% on 0.5 mg, and 36.4% on 1 mg. Understanding baseline event rates in control arms allows readers to distinguish expected background symptoms from the incremental risk caused by the medication.
| Adverse Reaction | Wegovy 2.4 mg Injection | Placebo Injection | Label Footnote |
|---|---|---|---|
| Nausea | 44% | 16% | |
| Diarrhoea | 30% | 16% | |
| Vomiting | 24% | 6% | 24% in Table 3; the section 6.1 narrative prints 25% |
| Constipation | 24% | 11% | |
| Abdominal pain | 20% | 10% | Includes abdominal pain upper and lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort and epigastric discomfort |
| Headache | 14% | 10% | |
| Fatigue | 11% | 5% | Includes fatigue and asthenia |
| Dyspepsia | 9% | 3% | |
| Dizziness | 8% | 4% | |
| Abdominal distension | 7% | 5% | |
| Eructation | 7% | <1% | |
| Hypoglycaemia in type 2 diabetes | 6% | 2% | |
| Flatulence | 6% | 4% | |
| Gastroenteritis | 6% | 4% | |
| Gastro-oesophageal reflux disease | 5% | 3% | |
| Gastritis | 4% | 1% | |
| Viral gastroenteritis | 4% | 3% | |
| Hair loss | 3% | 1% | Reported in the adult weight-reduction trials |
| Dysesthesia | 2% | 1% |
The Boxed Warning on Thyroid C-Cell Tumours
The Wegovy prescribing information carries a boxed warning headed "WARNING: RISK OF THYROID C-CELL TUMORS" regarding findings observed in animal exposure studies. The label text states: "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined."
The second bullet of that boxed warning states that Wegovy is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The label directs prescribers to counsel patients regarding potential symptoms of thyroid tumours, including a mass in the neck, difficulty swallowing (dysphagia), shortness of breath (dyspnea), and persistent hoarseness.
The Wegovy boxed warning states that routine monitoring of serum calcitonin or using thyroid ultrasound "is of uncertain value for early detection of MTC in patients treated with WEGOVY", and section 5.1 adds that such monitoring "may increase the risk of unnecessary procedures, due to the low-test specificity for serum calcitonin and a high background incidence of thyroid disease". In addition, section 5.1 of the Wegovy label notes that while cases of MTC have been reported postmarketing in patients treated with the related GLP-1 receptor agonist liraglutide, the data in those reports "are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans".
Labelled Warnings Requiring Specific Clinical Action
Specific warnings in the Wegovy and Ozempic prescribing information outline distinct clinical risks that require professional monitoring or treatment cessation. Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists, including Wegovy. In the Wegovy adult weight-reduction trials, acute pancreatitis was confirmed by adjudication in 4 Wegovy-treated patients (0.2 cases per 100 patient-years) and 1 placebo-treated patient (less than 0.1 cases per 100 patient-years). In Ozempic glycaemic-control trials, adjudicated acute pancreatitis occurred in 7 patients (0.3 cases per 100 patient-years) versus 3 comparator-treated patients (0.2 cases per 100 patient-years). Wegovy section 5.2 instructs that if pancreatitis is suspected, Wegovy should be discontinued.
Gallbladder disease occurred at higher rates in drug-treated groups than in control groups across trials. In randomised Wegovy trials in adults, cholelithiasis was reported by 1.6% of patients on Wegovy injection compared with 0.7% on placebo, while cholecystitis occurred in 0.6% on drug versus 0.2% on placebo. In paediatric patients aged 12 years and older, cholelithiasis affected 3.8% on Wegovy injection versus 0% on placebo. Section 5.3 notes that while substantial or rapid weight loss increases the risk of gallstones, the incidence of acute gallbladder disease was greater in Wegovy-treated patients than in placebo-treated patients even after accounting for the degree of weight loss.
Postmarketing surveillance identified acute kidney injury following volume depletion from gastrointestinal reactions. In the Wegovy weight-reduction trials, acute kidney injury occurred in 7 adults receiving Wegovy (0.4 cases per 100 patient-years) versus 4 receiving placebo (0.2 cases per 100 patient-years), occurring more frequently during dose titration and in adults with pre-existing renal impairment. Both labels state that postmarketing events of acute kidney injury, in some cases requiring hemodialysis, occurred mostly in patients experiencing severe nausea, vomiting, or diarrhoea.
Diabetic retinopathy complications require targeted screening in patients with pre-existing microvascular disease. In a 2-year trial of semaglutide 0.5 mg and 1 mg once-weekly injection in adults with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% of semaglutide-treated patients versus 1.8% on placebo. The absolute risk increase was larger in patients with a history of diabetic retinopathy at baseline (8.2% on drug versus 5.2% on placebo) than in those without baseline retinopathy (0.7% versus 0.4%). Both labels note that rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.
Regulatory authorities differ regarding non-arteritic anterior ischaemic optic neuropathy (NAION). On 2 to 5 June 2025 the EMA Pharmacovigilance Risk Assessment Committee (PRAC) concluded its review. It recommended adding NAION to the product information for Ozempic, Rybelsus and Wegovy as a very rare side effect, affecting up to 1 in 10,000 people. The Danish Medicines Agency reported 28 Danish cases as of 31 May 2025. In contrast, the terms NAION and optic neuropathy do not appear anywhere in the Wegovy prescribing information revised 1/2026 or the Ozempic prescribing information revised 5/2026.
| Clinical Risk | Reported Frequency, by Source | Control or Placebo Frequency | What the Label Directs the Prescriber to Do |
|---|---|---|---|
| Acute pancreatitis | 0.2 cases per 100 patient-years (Wegovy trials) | Less than 0.1 cases per 100 patient-years | Label directs the prescriber to discontinue if pancreatitis is suspected |
| Cholelithiasis (gallstones) | 1.6% in adult trials (Wegovy injection) | 0.7% | Label section 5.3: incidence was greater on Wegovy than placebo even after accounting for the degree of weight loss |
| Acute kidney injury | 0.4 cases per 100 patient-years (Wegovy trials) | 0.2 cases per 100 patient-years | Label notes risk is increased during titration and after dehydration from vomiting or diarrhoea |
| Diabetic retinopathy complications | 3.0% in 2-year diabetes cardiovascular risk trial | 1.8% | Monitor patients with a history of diabetic retinopathy for progression |
| Documented symptomatic hypoglycaemia | 29.8% on 1 mg when added to basal insulin (Ozempic trials) | 15.2% on placebo when added to basal insulin (Ozempic trials) | When starting, the label tells prescribers to consider reducing a concomitant insulin or insulin secretagogue dose |
| Non-arteritic anterior ischaemic optic neuropathy (NAION) | Up to 1 in 10,000 (EMA PRAC frequency category) | Unlisted in EMA PRAC assessment | EMA: contact a doctor without delay for sudden vision loss; stop treatment only if NAION is confirmed |
Delayed Gastric Emptying and Perioperative Precautions
Both the Wegovy and Ozempic prescribing information state that semaglutide delays gastric emptying, and both state that it is not recommended in patients with severe gastroparesis. Research cited in the pooled STEP analysis noted that a 12-week study of semaglutide 1.0 mg observed delayed gastric emptying on a paracetamol absorption test during the first hour. However, a 20-week study of semaglutide 2.4 mg did not identify such a delay. The mechanism of GLP-1 related nausea remains uncertain and may be primarily central rather than gastric.
The presence of residual stomach contents poses a clinical concern when patients undergo deep sedation or general anaesthesia. Wegovy section 5.11 notes rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists who had residual gastric contents despite adherence to preoperative fasting instructions. The label states available data are insufficient to determine whether modifying fasting intervals or temporarily holding the drug mitigates this risk.
Professional anaesthesia societies have published differing guidance regarding preoperative medication holds. In June 2023 the American Society of Anesthesiologists (ASA) issued consensus-based guidance that for patients on weekly dosing, clinicians should "consider holding GLP-1 agonists a week prior to the procedure/surgery". In October 2024 a joint multisociety guidance endorsed risk-based precautions, supporting the continuation of GLP-1 medications in many clinical situations without a routine hold.
Lean Mass Reductions Alongside Fat Loss
Dual-energy X-ray absorptiometry substudies show that absolute lean tissue decreases during semaglutide therapy, while lean mass as a proportion of total body weight increases. In the STEP 1 DEXA exploratory analysis of 140 participants followed for 68 weeks, participants receiving semaglutide 2.4 mg lost an average of 15.0% of total body weight compared with 3.6% in the placebo group. Total fat mass fell by 19.3%, regional visceral fat fell by 27.4%, and absolute lean body mass fell by 9.7% from baseline.
Evaluating body composition requires examining both absolute kilograms lost and relative tissue proportions. In the STEP 1 DEXA analysis, lean mass as a percentage of total body mass increased by 3.0 percentage points on semaglutide, whereas the percentage of total fat mass dropped by 3.5 percentage points. The ratio of lean mass to fat mass improved from 1.34 at baseline by 0.23 at week 68. This shift was larger in participants losing 15% or more of their total body weight, where the ratio rose by 0.41, compared with an increase of 0.03 in those losing less than 15%.
The STEP 1 DEXA analysis is the only body-composition data reviewed here, and it covers semaglutide 2.4 mg over 68 weeks. To track how tissue distribution changes, clinicians compare a baseline scan against a follow-up scan. Patients monitoring functional physical biomarkers can review baseline standards in our DEXA scan body composition guide and track muscular performance using our grip strength by age benchmark.
Trial Discontinuation Rates for Adverse Events
Permanent treatment discontinuation due to adverse reactions occurred in 6.8% of adults taking Wegovy 2.4 mg injection compared with 3.2% on placebo. The most frequent events prompting permanent discontinuation were gastrointestinal: nausea led to discontinuation in 1.8% of patients on Wegovy versus 0.2% on placebo, vomiting caused discontinuation in 1.2% versus 0%, and diarrhoea accounted for 0.7% versus 0.1%. Overall, permanent discontinuation specifically attributable to a gastrointestinal event occurred in 4.3% of Wegovy injection-treated adults compared with 0.7% of placebo-treated adults.
In the Wegovy cardiovascular outcomes trial, 8,803 patients received Wegovy injection for a median of 37.3 months and 8,801 received placebo for a median of 38.6 months. 16% of Wegovy-treated and 8% of placebo-treated patients discontinued study drug because of an adverse event. Safety collection in that trial was restricted to serious adverse events, events leading to study drug discontinuation, and prespecified adverse events of special interest.
Discontinuation rates were reported separately in each product's own trials. In placebo-controlled trials of Ozempic, permanent discontinuation due to gastrointestinal reactions occurred in 0.4% on placebo, 3.1% on 0.5 mg, and 3.8% on 1 mg. In trials evaluating oral semaglutide (Rybelsus), discontinuation for gastrointestinal reasons was documented in 1% of patients on placebo, 4% on 7 mg daily, and 8% on 14 mg daily. In the 68-week randomized withdrawal trial published by Rubino and colleagues (STEP 4), discontinuations for gastrointestinal events after week 20 were almost nil in both arms.
Hair Loss, Facial Changes, Mood and Cancer: What the Evidence Shows
Clinical trial records and postmarketing surveillance distinguish verified labelled reactions from unverified public claims. Hair loss is a documented clinical trial finding in weight-management populations. Table 3 of the Wegovy label reports hair loss in 3% of adult patients receiving 2.4 mg injection compared with 1% on placebo. In paediatric patients aged 12 years and older, Table 4 reports hair loss in 4% on Wegovy versus 0% on placebo. In the Ozempic prescribing information, hair loss is absent from clinical trial tables but appears as alopecia in the postmarketing section, where the label notes frequency and causality cannot be reliably estimated. A cross-sectional nail analysis presented at the 2026 EADV Congress reported nail detachment in 39 percent of GLP-1 users against 9 percent of nonusers. It has not been peer reviewed, and about half of those users reported nail changes before ever starting the medication. The investigators called the changes usually benign and not a reason to stop treatment on one’s own initiative.
No source read for this page reports trial data on facial volume, facial fat or skin laxity with semaglutide, and the term does not appear in any of the three prescribing information documents reviewed. There is no evidence either way to report.
Psychiatric warnings and surveillance show differing positions across regulatory assessments. Section 5.10 of the Wegovy prescribing information directs prescribers to monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviour, or unusual mood changes, instructing discontinuation if suicidal thoughts emerge. The Ozempic prescribing information contains no equivalent warning. On 11 January 2024 the FDA issued a Drug Safety Communication update stating its preliminary evaluation of reports did not demonstrate a clear relationship between GLP-1 receptor agonists and suicidal thoughts, but noted it cannot definitively rule out that a small risk may exist.
Outside the rodent C-cell finding, the Wegovy label reports no human cancer data either way. The Wegovy label notes postmarketing cases of MTC with liraglutide, stating data are insufficient to establish or exclude causality in humans. For wider metabolic pathways, readers can explore our analysis of GLP-1 receptor signalling in the brain and review baseline hepatic markers in our hepatic function panel guide.
| Concern or Claim | Reported Frequency or Trial Data | Source and Regulatory Status | Evidence Assessment |
|---|---|---|---|
| Hair loss (alopecia) | 3% Wegovy vs 1% placebo (adults); 4% vs 0% (pediatric) | Wegovy Table 3 and Table 4; Ozempic postmarketing section | Labelled adverse reaction in weight-management trials; voluntary report in Ozempic |
| Facial volume loss | No trial measured it; term absent from the Wegovy, Ozempic and Rybelsus labels reviewed | Absent from all FDA prescribing information reviewed | No evidence either way |
| Suicidal ideation or mood changes | Unquantified; no clear relationship in FDA review | Wegovy warning section 5.10; absent from Ozempic label; FDA communication | Precautionary label warning in Wegovy; FDA review found no clear relationship |
| Thyroid C-cell carcinoma | Observed in rodents; unquantified in humans | Boxed warning on Wegovy label; contraindicated in MTC and MEN 2 | Rodent carcinogenicity confirmed; human causal relationship undetermined |
Clinical Warning Signs to Raise with a Prescriber
Prescribing information for semaglutide outlines specific physical symptoms that require direct clinical evaluation by a medical professional. Severe, persistent abdominal pain, sometimes radiating to the back and with or without nausea or vomiting, is how the Wegovy label describes the presentation of acute pancreatitis. Section 5.2 of the label directs prescribers to discontinue Wegovy if pancreatitis is suspected. Anyone with that pain should seek urgent medical assessment and let the treating clinician make the decision about the drug.
Symptoms suggesting acute gallbladder complications also require clinical review. In Wegovy weight-reduction trials, cholelithiasis occurred in 1.6% of adults and 3.8% of paediatric patients aged 12 and older. Patients experiencing acute abdominal pain should report these symptoms to their physician for diagnostic evaluation, as section 5.3 notes gallbladder disease was greater on Wegovy than placebo even after accounting for the degree of weight loss.
The postmarketing acute kidney injury reports mostly followed nausea, vomiting or diarrhoea severe enough to cause dehydration. The Wegovy label notes that acute kidney injury occurred more frequently during dose titration and in patients with pre-existing renal impairment. Patients experiencing severe, persistent gastrointestinal fluid loss should contact their prescriber to evaluate hydration and kidney function before volume depletion progresses.
Patients taking semaglutide alongside other prescription therapies require medication review. Both labels state that rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, and that patients with a history of diabetic retinopathy should be monitored for progression. When initiating semaglutide in patients taking insulin or insulin secretagogues such as sulfonylureas, the label directs prescribers to consider reducing a concomitant insulin or insulin secretagogue dose to mitigate the risk of hypoglycaemia.
- Persistent severe abdominal pain. Report abdominal pain radiating to the back, with or without vomiting, so a clinician can evaluate for suspected acute pancreatitis.
- Signs of dehydration from fluid loss. Contact a doctor if severe nausea, vomiting, or diarrhoea prevents fluid intake, to prevent volume depletion and acute kidney injury.
- Sudden visual changes. Report visual disturbances or worsening eyesight promptly, especially if managing diabetic retinopathy or pre-existing microvascular disease.
- New neck mass or persistent hoarseness. Inform a healthcare provider of neck swelling, dysphagia, dyspnea, or hoarseness, as outlined in the boxed warning regarding thyroid tumours.
Frequently Asked Questions
What are the most common semaglutide side effects?
The most common semaglutide side effects are gastrointestinal symptoms including nausea, diarrhoea, vomiting, and constipation. In clinical trials of Wegovy 2.4 mg injection in adults, nausea occurred in 44% of patients compared with 16% on placebo, diarrhoea in 30% versus 16%, vomiting in 24% versus 6%, and constipation in 24% versus 11%. Overall, 73% of Wegovy-treated participants reported gastrointestinal events versus 47% on placebo. In diabetes trials of Ozempic, nausea occurred in 15.8% on 0.5 mg and 20.3% on 1 mg compared with 6.1% on placebo. In the pooled STEP 1 to 3 analysis of semaglutide 2.4 mg, 98.1% of gastrointestinal adverse events were mild or moderate and 99.5% were non-serious.
Is semaglutide safe?
Clinical trials establish that commercial semaglutide formulations have well-documented safety profiles under physician supervision, with adverse events consisting largely of non-serious gastrointestinal complaints. However, specific serious risks carry regulatory warnings. The Wegovy prescribing information carries a boxed warning regarding thyroid C-cell tumours observed in rodents and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. In clinical trials, acute pancreatitis occurred in 0.2 cases per 100 patient-years on Wegovy versus less than 0.1 on placebo. Serious complications such as acute kidney injury and gallbladder disease occur far less frequently than digestive complaints but require professional monitoring.
Does semaglutide cause hair loss?
Hair loss is a documented adverse reaction in clinical trials of semaglutide for weight management, though it affects a small minority of participants. In adult clinical trials of Wegovy 2.4 mg injection, hair loss was reported by 3% of participants compared with 1% on placebo. In paediatric patients aged 12 years and older taking Wegovy, hair loss was reported by 4% on drug versus 0% on placebo. Hair loss is not listed in the clinical trial adverse reaction tables for Ozempic, but alopecia is listed in its postmarketing section where the label notes that reporting rates cannot reliably establish frequency or causality.
Can semaglutide cause cancer?
In rodent studies, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours, which is why the Wegovy prescribing information carries a boxed warning. It is unknown whether Wegovy causes thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of rodent C-cell tumours has not been determined. The drug is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. Beyond the rodent C-cell finding, the only human data the Wegovy label reports are postmarketing cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, which the label says are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.
Does semaglutide cause muscle loss?
Absolute lean body mass decreases during semaglutide therapy alongside substantial fat loss. In the STEP 1 dual-energy X-ray absorptiometry (DEXA) substudy of 140 participants receiving semaglutide 2.4 mg for 68 weeks, total body weight fell by 15.0% and total lean body mass fell by 9.7% from baseline. However, fat mass fell by 19.3% and visceral fat fell by 27.4%. Because fat mass decreased more than lean tissue, lean body mass as a proportion of total body weight actually increased by 3.0 percentage points, and the lean-to-fat mass ratio improved from 1.34 by 0.23 at week 68.
What are the serious side effects of semaglutide?
Serious side effects carrying label warnings include acute pancreatitis, acute gallbladder disease, acute kidney injury, complications of diabetic retinopathy, and severe hypoglycaemia when combined with insulin or sulfonylureas. In Wegovy adult trials, acute pancreatitis was adjudicated in 0.2 cases per 100 patient-years versus less than 0.1 on placebo, and acute kidney injury occurred in 0.4 cases per 100 patient-years versus 0.2 on placebo. In a 2-year trial of semaglutide 0.5 mg and 1 mg once-weekly injection in adults with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% on drug versus 1.8% on placebo.
Does semaglutide affect your eyes?
Semaglutide can influence ocular complications, primarily in individuals with pre-existing diabetic eye disease. In a 2-year trial of semaglutide 0.5 mg and 1 mg once-weekly injection in adults with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% of semaglutide-treated patients compared with 1.8% on placebo, with higher absolute rates among those entering the trial with baseline retinopathy (8.2% versus 5.2%). Rapid improvement in glucose control is associated with temporary worsening of diabetic retinopathy. In Europe, the EMA recommended adding non-arteritic anterior ischaemic optic neuropathy (NAION) as a very rare side effect, affecting up to 1 in 10,000 patients, though NAION does not appear on US FDA labels.
Are semaglutide side effects worse for women?
Clinical trial adverse reaction tables generally report adverse event frequencies across pooled cohorts rather than publishing broken-out gender breakdowns for common digestive reactions. However, specific musculoskeletal differences appeared in outcomes data. In the Wegovy cardiovascular outcomes trial, fractures of the hip and pelvis were reported more frequently in female patients receiving Wegovy (1%, 24 of 2,448) than in female patients on placebo (0.2%, 5 of 2,424). Gastrointestinal event rates like nausea and vomiting occur widely across both sexes in trial cohorts.
Does semaglutide cause gallstones?
Yes, semaglutide increases the incidence of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) in clinical trials. In adult weight-reduction trials of Wegovy 2.4 mg injection, cholelithiasis occurred in 1.6% of patients on drug compared with 0.7% on placebo, while cholecystitis was reported by 0.6% on Wegovy versus 0.2% on placebo. In paediatric patients aged 12 and older, cholelithiasis occurred in 3.8% on Wegovy versus 0% on placebo. Section 5.3 of the Wegovy prescribing information emphasizes that gallbladder disease was greater on Wegovy than on placebo even after accounting for the degree of weight loss.
Related
- Semaglutide Side Effects Timeline: Onset, Duration, and Recovery
- Ozempic vs Wegovy: Indications, Dosing, and Safety Profiles
- Compounded vs Brand Semaglutide: Regulatory and Clinical Differences
- DEXA Scans for Body Composition and Lean Mass Tracking
- Grip Strength Norms by Age and Functional Muscle Benchmarks